[2]DiSilvestro P, et al. SOLO1 Investigators. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J...
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. Gynecol Oncol. 2022 Sep;166(3):425-431. doi: 10.1016/j.ygyno.2022.06.017. Epub 2022 Jul 5. PMID: 35803835; PMCID: PMC9909678...
9. Yusuke Kawanaka, et al.The impact of HRD mutation on survival in patients with KRAS-mutated advanced pancreatic cancer: A real-world database study.2024ASCO Breakthrough.Abstract #221. 10. 2024 ASCO Abstract 4018 11....
[2]DiSilvestro P, et al. SOLO1 Investigators. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023 Jan 20;41(3):609-617. doi: 10.1200/JCO.22.01549. ...
既往检测BRCA1/2检测阴性,寻求PARP抑制剂获益的患者。 参考文献: 1. Cadoo K, Simpkins F, Mathews C, et al. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency s...
3. Marth C, Park-Simon T, Aghajanian C, et al. Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour ...
3. Marth C, Park-Simon T, Aghajanian C, et al. Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour ...
“From a preventive standpoint, uterine serous cancer could be a phenotype of hereditary breast and ovarian cancer syndrome. And if so, germline mutation carriers opting for surgical risk reduction could be offered hysterectomy at the time of risk-reducing bilateral salpingo-oophorectomy,” he said...
CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC) CCNE1扩增定义晚期高级别卵巢癌(HGOC)BRCAwt/HRDneg的亚组预后良好 F. Blanc-Durand Background Around 50% of...
图1.BRCA参与DNA损伤修复的过程 Lord CJ, Ashworth A. Nat Rev Cancer,2016 图2.BRCA突变和PARPi的合成致死作用 Banerjee S, Kaye SB,Ashworth A. Nat Rev Clin Oncol,2010 胚系突变(germline mutation)和体细胞突变(somatic mutation) EOC患者中gBRCA1/2突变的...